CAS 461432-23-5 Dapagliflozin Intermediate
Port: Shanghai, China
|Other Names||Dapagliflozin Intermediate|
What is Dapagliflozin?
Dapagliflozin is a new type of antidiabetic drug jointly developed by Bristol-Myers Squibb and AstraZeneca. It was approved by the European Medicines Agency (EMA) on November 12, 2012 and is the first to be approved. SGLT2 inhibitors for the treatment of type 2 diabetes are important candidates for the treatment of diabetes. They are used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Function and Application
Dapagliflozin A sodium-glucose transporter 2 inhibitor,Pharmaceutical raw materials.